

CURRICULUM VITAE

MARK C. KELLEY, M.D., MMHC, FACS

CURRENT POSITION AND OFFICE ADDRESS:

Mark C. Kelley, MD, MMHC, FACS

Associate Professor of Surgery
Chief, Division of Surgical Oncology and Endocrine Surgery
Vanderbilt University Medical Center
597 Preston Building
2200 Pierce Avenue
Nashville, TN 37232-6860

Email: mark.kelley@vanderbilt.edu
Phone: 615-322-2391

DATE OF BIRTH August 17, 1964

EDUCATION

COLLEGE	University of Florida, Gainesville, Florida Major: Interdisciplinary Studies 7/82-5/85 Bachelor of Science (High Honors) 5/23/85
MEDICAL SCHOOL	University of Florida, Gainesville, Florida Program: Medicine 8/85-5/89 Doctor of Medicine (Honors) 5/27/89
INTERNSHIP & RESIDENCY	University of Florida, Gainesville, Florida General Surgery 7/89-6/95 Surgical Research Resident 7/91-6/92 Chief Resident 7/94-6/95
FELLOWSHIP	John Wayne Cancer Institute, Santa Monica, California Surgical Oncology Fellow 7/95-7/97
GRADUATE	Vanderbilt-Owen Graduate School of Management Nashville, Tennessee Master of Management in Health Care 08/08–09/09

LICENSURE

Tennessee Board of Medical Examiners
License # MD-29494 Active
Certified 7/97 Expires 8/10

The Medical Board of California
License # GO-81320 Inactive
Certified 4/95 Expired 8/97

Florida Board of Medical Examiners

Alpha Omega Alpha, Junior Class Election (1988)
Robert Donohoe Award in General Surgery (1989)
Florida Obstetric and Gynecologic Society Award (1989)
Walter Oppelt Award for Pharmacology Research (1989)
Surgical Research Award (1992)
Outstanding Teaching Resident (1995)
Edward R. Woodward Award (1995)
Castle-Connelly Best Doctors in America (2007-present)

MEMBERSHIPS

Association for Academic Surgery
American Association for Cancer Research
American College of Surgeons (Fellow, 10/01)
American College of Surgeons Oncology Group
American Society for Clinical Oncology
American Society of Breast Surgeons
Eastern Cooperative Oncology Group
Society for Surgery of the Alimentary Tract
Society of Surgical Oncology
Southeastern Surgical Congress
Vanderbilt-Ingram Cancer Center
Edward R. Woodward Society
H. William Scott, Jr. Society
The Nashville Surgical Society

EDITORIAL BOARDS

Ad Hoc Reviewer, Journal of Surgical Research, 1999-Present
Ad Hoc Reviewer, Annals of Surgical Oncology, 2000-Present
Ad Hoc Reviewer, New England Journal of Medicine, 2003
Ad Hoc Reviewer, Cancer, 2004-Present
Ad Hoc Reviewer, Surgery, 2005
AVON/NCI P01 Reviewer, NIH/NCI, 2007-2008

TEACHING EXPERIENCE

Vanderbilt University School of Medicine
Division of Surgical Oncology and Endocrine Surgery
Assistant Professor of Surgery 07/97 – 06/03
Associate Professor of Surgery 07/03- Present

University of Southern California
Department of Surgery
Instructor in Surgery 1996

MENTORING EXPERIENCE

CLINICAL:

1. **Kenneth Richards, M.D.:** Endocrine Surgery Fellow, 1999-2000.
Current Position: General / Endocrine Surgeon, Private Practice, Roanoke VA.
2. **Glen Balch, M.D.:** Surgical Research Resident 2002-2003.
Current Position: Surgical Oncologist, UT Southwestern Medical Center, Dallas TX.
3. **Laura Lawson, M.D.:** Breast Surgery Fellow, 2003-2004.
Current Position: Breast Surgeon, Private Practice, Nashville TN.
4. **Rachel Forbes, M.D.:** Research Student, 2004-2005.
Current Position: Chief Resident, General Surgery, VUMC, Nashville TN.
5. **Alison Hatmaker, M.D.:** Breast Surgery Fellow, 2005-2006; 2008-2009.
Current Position: Breast Surgeon, Private Practice, Louisville KY.
6. **Brian Gray, M.D.:** Research Student, 2005-2006.
Current Position: Resident, General Surgery, University of Michigan, Ann Arbor MI.
7. **Alfred Mansour, M.D.:** Research Resident, 2007-2008.
Current Position: Resident, Orthopaedics, VUMC, Nashville TN.

RESEARCH:

1. **Jao Jih Ou:** Dissertation for the degree of PhD in Biomedical Engineering. "Development of Modality-Independent Elastography as a Method of Breast Cancer Detection", 2006-2007. Committee Member - Michael Miga PhD, Chair.
2. **William Hardesty:** Dissertation for the degree of PhD in Chemistry. "Histology-Directed MALDI-MS for the Identification of Protein Biomarkers in Melanoma", 2007-2008. Committee Member – Richard Caprioli PhD, Chair.
3. **Matthew Keller:** Dissertation for the degree of PhD in Biomedical Engineering. "Optical Spectroscopy Imaging for the Evaluation of Breast Cancer Surgical Margins", 2008-2009. Committee Member – Anita Mahadevan-Jansen PhD, Chair.

RESEARCH INTERESTS

CLINICAL:

Quality Improvement and Clinical Outcomes Analysis in Melanoma and Breast Cancer
 Clinical Trials of Molecular Targeted Therapy for Melanoma and Breast Cancer
 Clinical Trials of Regional Lymph Node Management in Melanoma and Breast Cancer
 Surgical Treatment of Unusual Cutaneous Malignancies
 Application of New Technologies in Cancer Treatment
 Tissue Acquisition and Analysis for Personalized Cancer Therapy

BASIC SCIENCE:

Molecular and Cellular Biology of Melanoma and Breast Cancer
 Identification of Novel Biomarkers of Treatment Response and Outcome in Melanoma
 Novel Preclinical Models for the Evaluation of Molecular Targeted Therapy in Melanoma

RESEARCH PROTOCOLS

CLINICAL:

- 1) Sentinel node mapping for breast cancer: a pilot study (VCC BRE-9702). **Principal Investigator**. No extramural funding. (Closed)
- 2) Early detection of occult micrometastases by lymph node mapping and RT -PCR in patients with invasive breast cancer: A multi-center trial (VCC BRE-9703). **Site Principal Investigator**. Funded by the Department of Defense (DOD) through Moffitt Cancer Center. (Closed)
- 3) A phase III randomized double-blind trial of immunotherapy with a polyvalent melanoma vaccine (C-VAX) plus BCG versus placebo plus BCG as a post-surgical treatment for stage IV melanoma (VCC MEL-9807). **Site Principal Investigator**. Funded by the National Cancer Institute (NCI) and CancerVax^R Corporation (Closed).
- 4) A phase III randomized double-blind pivotal trial of immunotherapy with BCG plus a polyvalent melanoma vaccine (C-VAX) versus BCG plus placebo as a post-surgical treatment for stage III melanoma (VCC MEL-9838). **Site Principal Investigator**. Funded by the NCI and CancerVax^R Corporation (Closed).
- 5) A multicenter trial of adjuvant interferon alfa-2b for melanoma patients with early lymph node metastasis detected by lymphatic mapping and sentinel lymph node biopsy (IN MEL-9701). **Site Principal Investigator**. Funded by Schering-Plough Corporation. (Closed)
- 6) Local excision alone for selected patients with DCIS of the breast (ECOG BRE-E5194). **Co-Investigator**. Funded by the Eastern Cooperative Oncology Group (ECOG). (Closed)
- 7) Evaluation of lumpectomy, tamoxifen, and irradiation of the breast compared with lumpectomy plus tamoxifen in women 70 years of age or older with breast cancer that is less than or equal to 2 cm in size: A phase III study (ECOG BRE-C9343) **Site Co-Investigator**. Funded by ECOG (Closed).
- 8) NSABP Protocol P2: Study of tamoxifen and Raloxifene for the Prevention of Breast Cancer (IN P-9901) **Site Principal Investigator**. Funded by the National Surgical Adjuvant Breast and Bowel Program (NSABP) (Closed to accrual).
- 9) Sentinel lymph node mapping in vulvar carcinoma (VCC GYN-9921) **Co-Investigator**. No extramural funding. (Closed)
- 10) Identification of intraductal breast pathology in high-risk women: a multicenter trial (IN BRE-9945) **Principal Investigator**. Funded by Pro-Duct Health Corporation. (Closed)
- 11) A pilot study of molecular-based therapy utilizing neoadjuvant paclitaxel and concurrent radiation in stage II/III breast cancer (VCC BRE-9936) **Co-Investigator**. Funded by the NCI (SPORE in breast cancer, Vanderbilt-Ingram Cancer Center P50-CA-98131-01) (Closed).
- 12) A prognostic study of sentinel node and bone marrow micrometastasis in women with clinical T1 or T2 No Mo breast cancer. (ACoSOG trial Z-10, IN SUR-0043) **Site Principal Investigator**. Funded by NCI through ACoSOG. (Closed).
- 13) A randomized trial of axillary node dissection in women with clinical T1 or T2 No Mo breast cancer who have a positive sentinel node. (ACoSOG trial Z-11, IN SUR-0044) **Site Principal Investigator**. Funded by NCI through ACoSOG (Closed).
- 14) A prospective follow-up study evaluating ductal lavage cytology in women at high risk of developing breast cancer. **Site Principal Investigator**. (Closed).
- 15) Nashville Breast Health Study. **Co-Investigator**. Funded by the NCI (R-01 to Dr. Wei Zheng).
- 16) HER (erbB) tyrosine kinase inhibitors in treatment-naïve operable breast cancer. **Co-Principal Investigator**. Funded by the NCI (SPORE in breast cancer, Vanderbilt-Ingram Cancer Center P50-CA-98131-01). (Closed)
- 17) EGFR pathway modulation in DCIS of the breast. **Co-Investigator**. Funded by the NCI (R-21-CA-101357-01 to Dr Cristina Truica) (Closed).

- 18) Inhibition of NF- κ B signaling in melanoma therapy. **Co-Investigator**. Funded by the NIH/FDA (FD-R-002-33-01 to Dr. Jeffrey Sosman).
- 19) Multicenter selective lymphadenectomy trial II (MSLT-II). **Site Principal Investigator**. Funded by the NCI through John Wayne Cancer Institute.
- 20) Optical spectroscopy for the evaluation of surgical margins in breast conserving therapy. **Co-Investigator**. Pilot project funded by the NCI (SPORE in breast cancer, Vanderbilt-Ingram Cancer Center P50-CA-98131-01)
- 21) A two-arm phase II correlative clinical trial of MLN8237, a selective Aurora Kinase A (AURKA) inhibitor, in patients with resectable stage III or IV melanoma or unresectable stage III or IV disease. **Co-Principal Investigator**. Application for FDA Orphan Drug R-01 funding submitted 02/08.

BASIC SCIENCE:

- 1) The role of NF- κ B dysregulation in melanoma tumor progression. **Collaborator**. Funded by the NCI, R-01 (PI: Ann Richmond, PhD).
- 2) Preclinical evaluation of autologous dendritic cells loaded with tumor-derived apoptotic bodies for immunotherapy of melanoma. **Principal Investigator**. Funded by the American Cancer Society Institutional Research Grant to Vanderbilt-Ingram Cancer Center (IRG-58-009-42) and the Vanderbilt Physician Scientist Development Program, 01/00-12/00.
- 3) Molecularly-Based Targeted Therapy of Melanoma. **Co-Investigator**. Translational Grant Funded by the V Foundation (Ann Richmond, PhD).

BIBLIOGRAPHY

Original Manuscripts

1. O'Malley CA, Hautamaki RD, **Kelley MC**, Meyer EM. Effects of ovariectomy and estradiol benzoate on high affinity choline uptake, acetylcholine synthesis and release from rat cerebral cortical synaptosomes. Brain Research 403:389-392, 1987.
2. **Kelley MC**, Raizada MK, Meyer EM. Pharmacological characterization of high affinity choline transporters in primary neuronal cultures in rat brain. Neuropharmacology 27(8): 837-842, 1988.
3. **Kelley MC**, Hocking MP, Marchand SD, Sninsky CA. Ketorolac prevents postoperative small intestinal ileus in rats. American Journal of Surgery 165(1): 107-112, 1993.
4. Espat NJ, Cheng G, **Kelley MC**, Vogel SB, Sninsky CA, Hocking MP. Vasoactive intestinal peptide and substance P receptor antagonists improve postoperative ileus. Journal of Surgical Research 68(6): 719-723, 1995.
5. Jones RC, **Kelley MC**, Gupta RK, Nizze JA, Yee R, Leopoldo Z, Qi K, Stern S, Morton DL. Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: An immunologic survival model. Annals of Surgical Oncology 3(5): 437-445, 1996.
6. Ravindranath MH, Bauer PM, Amiri AA, Miri SM, **Kelley MC**, Morton DL. Cellular cancer vaccine induces delayed-type hypersensitivity reaction and augments antibody response to tumor-associated carbohydrate antigens better than soluble lysate cancer vaccine. Anti-Cancer Drugs 8: 217-224, 1997.
7. Ravindranath MH, Amiri AA, Bauer PM, **Kelley MC**, Essner R, Morton DL. Endothelial-selectin ligands sialyl-Lewis^x and sialyl-Lewis^a are differentiation antigens immunogenic in human melanoma. Cancer 79: 1686-1697, 1997.
8. Bostick P, Essner R, Sarantou T, **Kelley MC**, Glass E, Foshag LJ, Stern S, Morton DL. Intraoperative lymphatic mapping for early-stage melanoma of the head and neck. American Journal of Surgery. 174:536-539, 1997.
9. Ravindranath MH, **Kelley MC**, Jones RC, Amiri AA, Bauer PM, Morton DL. Ratio of IgG:IgM antibodies to Sialyl-Lewis^x and GM₃ correlates with tumor growth after immunization with melanoma cell vaccine with different adjuvants. International Journal of Cancer 75:117-24, 1998.
10. **Kelley MC**, Jones RC, Gupta R, Wanek L, Morton DL. Tumor-associated antigen TA-90 immune complex assay detects occult metastases in early-stage melanoma. Cancer 83(7): 1355-61, 1998.
11. Bostick P, Essner R, Glass E, **Kelley MC**, Foshag LJ, Morton DL. Comparison of blue dye and probe-assisted intraoperative lymphatic mapping in melanoma to identify sentinel nodes in 100 lymphatic basins. Annals of Surgery 134(1):43-9, 1999.
12. Essner, R Conforti A, **Kelley MC**, Foshag LJ, Stern S, Morton DL. Efficacy of lymphatic

- mapping, sentinel lymphadenectomy, and selective complete lymph node dissection as a therapeutic procedure for early-stage melanoma. Annals of Surgical Oncology 6(5):442-9, 1999.
13. Giuliano AE, Haigh PI, Brennan MB, Hansen NM, **Kelley MC**, Ye W, Glass E, Turner RR. Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. Journal of Clinical Oncology 18(13):2553-9, 2000.
 14. Chakravarthy A, Nicholson B, **Kelley MC**, Beauchamp RD, Johnson D, Frexes-Steed M, Simpson J, Shyr Y, Pietenpol J. A pilot study of neoadjuvant paclitaxel and radiation with correlative molecular studies in stage II/III breast cancer. Clinical Breast Cancer 1(1):68-20, 2000.
 15. Bilchik A, Miyashiro M, **Kelley MC**, Kuo C, Fujiwara Y, Nakamori S, Monden M, Hoon DS. Molecular detection of metastatic pancreatic carcinoma cells using multimarker reverse transcriptase-polymerase chain reaction assay. Cancer 88(5) 1037-44, 2000.
 16. **Kelley MC**, Hsueh E, Jones RC, Gupta RK, Yee R, Stern S, Morton DL. Tumor-associated antigen TA-90 immune complex assay predicts recurrence and survival after surgical resection of stage I-III melanoma. Journal of Clinical Oncology 19(4):1176-82, 2001.
 17. Dupont EL, Kamath VJ, Ramnath EM, **Kelley MC**. et al. The role of lymphoscintigraphy in the management of the patient with breast cancer. Annals of Surgical Oncology 8(4):354-360, 2001
 18. Dooley WC, Lyung BM, Veronesi U, Cazzaniga M, Elledge RM, O'Shaughnessy JA, Kuerer HM, Hung DT, Khan SA, Phillips RA, Ganz PA, Euhus DM, Esserman LJ, Haffty BG, King BL, **Kelley MC**, et al.. Ductal lavage for detection of cellular atypia in women at high risk of breast cancer. Journal of the National Cancer Institute 93(21):1624-1632, 2001.
 19. Molpus KL, **Kelley MC**, Johnson JE, Martin WH, Jones HW. Sentinel lymph node detection and microstaging in vulvar carcinoma. Journal of Reproductive Medicine 46(10) 863-869, 2001.
 20. Ludwig V, Rice MH, Martin WH, **Kelley MC**, Delbeke D. 2-Deoxy-2-[¹⁸F]Fluoro-D-Glucose Positron Emission Tomography Uptake in a Giant Adrenal Myelolipoma. Molecular Imaging and Biology 4(5):355-358, 2002
 21. Balch GC, Mithani SK, Richards K, Beauchamp RD, **Kelley MC**. Prospective evaluation of lymphatic mapping and sentinel lymphadenectomy after preoperative therapy for stage II and III breast cancer. Annals of Surgical Oncology 10(6):616-621, 2003.
 22. Lawson LL, Sandler M, Martin W, Beauchamp RD, **Kelley MC**. Preoperative lymphoscintigraphy and internal mammary sentinel lymph node biopsy does not enhance the accuracy of lymphatic mapping for breast cancer. The American Surgeon, 70(12) 1050-55, 2004.
 23. Balch GC, Mithani SK, Simpson J, **Kelley MC**. Accuracy of gross evaluation of surgical margin status in women undergoing partial mastectomy for breast malignancy. The

American Surgeon, 71(7), 22-7, 2005.

24. Forbes RC, Balch GC, **Kelley MC**. Selective Use of Intraoperative Touch Prep Analysis of Sentinel Nodes in Breast Cancer. The American Surgeon, 71(1):22-27, 2005.
25. Chakravarthy B, **Kelley MC**, McLaren B, Truica CI, Billheimer D, Mayer IA, Grau AM, Johnson DH, Simpson JF, Beauchamp RD, Jones C, Pietenpol J. Neoadjuvant concurrent paclitaxel and radiation in stage II/III breast cancer. Clinical Cancer Research, 12(5):1570-6, 2006.
26. Tomkova K, El-Rifai W, Vilgelm A, **Kelley MC**, Wang T, Zaika AI. The gastrin gene promoter is regulated by p73 protein isoforms in tumor cells. Oncogene, 25(44):6032-6, 2006.
27. Yankeelov TE, Lepage M, Chakravarthy AB, Broome EE, Niermann KJ, **Kelley MC**, Meszoely IM, Mayer IA, Herman CR, McManus K, Price RR, Gore JC. Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: Initial results. Magnetic Resonance Imaging, 25(1):1-13, 2007.
28. El-Rifai W, **Kelley MC**, Belkiri A. t-Darpp promotes cancer cell survival by upregulation of Bc12 through Akt-dependent mechanism. Cancer Research. 68(2):395-403, 2008.
29. Tastas AD, Keedy VL, Florell SR, Simpson JF, Coffin CM, **Kelley MC**, Cates, JMM. Foamy Cell Angiosarcoma: A Rare and Deceptively Bland Variant of Cutaneous Angiosarcoma. Submitted to Journal of Cutaneous Pathology, 2009.

Book Chapters and Review Articles

1. Conforti AM, Ollila DW, **Kelley MC**, Morton DL. Update on active specific immunotherapy with melanoma vaccines. Journal of Surgical Oncology 66:55-64, 1997.
2. Ollila DW, **Kelley MC**, Gammon G, Morton DL. Overview of melanoma vaccines: active specific immunotherapy for melanoma patients. Seminars in Surgical Oncology 14:328-336, 1998.
3. **Kelley MC**, Ollila DW, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for melanoma. Seminars in Surgical Oncology, 14:283-90, 1998.
4. **Kelley MC**, Giuliano AE. "Lymphatic mapping and sentinel lymphadenectomy for breast cancer" in The Breast: Comprehensive Management of Benign and Malignant Diseases. 2nd Ed. KI Bland and EM Copeland III, Eds. W.B. Saunders, pp 1100-1111, 1998.
5. Scoggins CR, **Kelley MC**. Current surgical therapy of rectal cancer. Colorectal Cancer: Index and Reviews 1(4):1-6, 2000.
6. Balch GC, Mithani SK, **Kelley MC**. Intraoperative evaluation of surgical margins in breast-conserving therapy. The Breast: Comprehensive Management of Benign and Malignant Diseases. 3rd Ed., 2003.
7. **Kelley MC**, Hansen N, McMasters K. Lymphatic Mapping and Sentinel Lymphadenectomy for Breast Cancer. The American Journal of Surgery 188(1) 49-61, 2004.
8. Hatmaker AR, Meszoely IM, **Kelley MC**. Surgical management of carcinoma *in situ* and proliferative lesions of the breast. Mastery of Surgery. 5th Ed, JE Fischer and KI Bland, Eds. W.B. Lippincott, Williams and Wilkins, pp 521-530, 2006.

Abstracts and Poster Presentations

1. **Kelley MC**, Koppenaar D, Raizada MK, Meyer EM. Pharmacology and Turnover of High Affinity Choline Uptake and Acetylation in Primary Brain Cell Cultures. Presented at the Society of Neuroscience, 1986.
2. **Kelley MC**, Marchand SD, Hocking MP, Sninsky CA. Ketorolac Improves Small Bowel Transit in Rats with Postoperative Ileus. Presented at the 34th Annual University Surgical Resident Conference, Society of University Surgeons, 1992.
3. **Kelley MC**, Langham Jr MR, Hocking MP. Methemoglobinemia is Induced by Endotoxin Through a Nitric Oxide Dependent Pathway. Presented at the American Academy of Pediatrics, Section on Surgery, 1993.
4. Jones RC, **Kelley MC**, Gupta R, Nizze JA, Yee R, Leopoldo Z, Morton DL. Response to Melanoma Cell Vaccine in AJCC Stage III Melanoma: An Immunologic Survival Model. Presented at the Society of Surgical Oncology, 1996.
5. **Kelley MC**, Jones RC, Gupta R, Wanek L, Morton DL. Tumor-Associated Antigen TA-90 Predicts Recurrence, Lymph Node Status and Survival in Stage I and II Melanoma. Presented at the Society of Surgical Oncology, 1996.
6. Jones RC, **Kelley MC**, Gupta R, Morton DL. IgG Subclass Response to Melanoma Cell Vaccine: The Gamma-4 Connection. Proc Am Assoc Cancer Research 37:477, 1996.
7. Gupta R, Nizze JA, Yee R, **Kelley MC**, Leopoldo Z, Stiles A, Dickey A, O'Neill K, Halpin A, Morton DL. Prospective Evaluation of a 90 kD Glycoprotein Tumor-Associated Antigen in Melanoma Patients. Proc Am Soc Clin Oncol 15:93, 1996.
8. Gupta RK, Giuliano AE, **Kelley MC**, Yee R, Leopoldo Z, Morton DL. Clinical Significance of 90 kD Tumor-Associated Antigen-Specific Immune Complexes in Breast Cancer Patients. J Tumor Marker Oncology 11:44, 1996.
9. Essner R, **Kelley MC**, Foshag LJ, Cochran A, Wen D-R, Stern S, Wanek LA, Conforti A, Morton DL. Intraoperative Lymphatic Mapping and Selective Lymphadenectomy in 481 Patients with Early-Stage Melanoma. Presented at the American College of Surgeons, 1996.
10. Essner R, Nguyen TX, **Kelley MC**, Hoon DSB. Human Gastrointestinal Carcinomas Respond to Interleukin-4 Through a Functional IL-2 Receptor Gamma Chain. Presented at the Society of Surgical Oncology, 1997.
11. **Kelley MC**, Nguyen TX, Hoon DSB, Essner R. Regulation of Hepatocyte Growth Factor-Induced Cell Cycle Progression in Pancreatic Carcinoma. Presented at the Society of Surgical Oncology, 1997.
12. Ravindranath MH, Amiri AA, **Kelley MC**, Jones RC, Morton DL. Tumor Progression After Immunotherapy With Melanoma Cell Vaccine is Predicted by the Ratio of IgG to IgM Antibodies to Sialyl-Lewis^x and GM₃ in a Murine Model. Proc Am Assoc Cancer Res.

- 38:398, 1997.
13. Essner R, Nguyen TX, **Kelley MC**, Hoon DSB. Molecular Role of the Interleukin-2 Receptor Common Gamma Chain Subunit (IL-2R γ c) in Controlling Cell Cycle Progression of Human Non-Small Cell Lung Carcinomas by Interleukin-4. Proc Am Assoc Cancer Res. 38:554, 1997.
 14. Essner R, Conforti A, **Kelley MC**, Wanek L, Morton DL. Cost Effective Management of the Inguinal Nodes in Early-Stage Melanoma. Melanoma Res 7(Suppl 1):529, 1997.
 15. **Kelley MC**, Bostick P, Bilchik A, Foshag LJ, Essner R, Kuo C, Conrad A, Boasberg PD, Hoon DSB. Molecular Detection of Pancreatic Carcinoma (PC) with a Multiple-Marker RT-PCR Assay. Proc Am Soc Clin Oncol 16:293a, 1997.
 16. Bostick P, Sarantou T, Essner R, **Kelley MC**, Glass E, Foshag LJ, Morton DL. Intraoperative Lymphatic Mapping for Early-Stage Melanoma of the Head and Neck. Presented at The Society of Head and Neck Surgeons, 1997.
 17. **Kelley MC**, Nguyen TX, Hoon DSB, Essner R. Human Pancreatic Carcinoma Growth and Invasion is Regulated by c-met and Interleukin-4 Receptor Gene Expression. Presented at The Society for Surgery of the Alimentary Tract, 1997.
 18. Essner R, Conforti A, **Kelley MC**, Wanek L, Stern S, Morton DL. Efficacy of selective lymphadenectomy as a therapeutic procedure for early-stage melanoma. Presented at The Society of Surgical Oncology, 1998.
 19. **Kelley MC**, Leach SD, Simpson JW, Page DL, Beauchamp RD. Routine Review of Histopathology Affects Surgical Management of Melanoma. Presented at the Association for Academic Surgery, 1998.
 20. Roberts JR, Leach SD, **Kelley MC**, Tarpley JL, Sharp K, Beauchamp RD. Transthoracic esophagectomy increases life-threatening complications and length of stay compared to transhiatal esophagectomy. Presented at the Society of Thoracic Surgery, 1999.
 21. Ollila DW, **Kelley MC**, Hansen N, Giuliano AE. Independent experience of SSO fellowship trained surgical oncologists with lymphatic mapping for breast cancer. Presented at The Society of Surgical Oncology, 1999.
 22. Roberts JR, Leach SD, **Kelley MC**, Tarpley JL, Sharp K, Beauchamp RD. Multidisciplinary surgical management and low-dose neoadjuvant radiotherapy decrease operative morbidity and mortality after esophagectomy. Proc Am Soc Clin Oncol 19:290a, 2000.
 23. Donovan J, Roberts JR, Beauchamp RD, Berlin J, Chakravarthy A, **Kelley MC**, Pearson AS. Changing patterns of metastasis following complete response to neoadjuvant therapy in patients with adenocarcinoma of the gastroesophageal junction. Presented at the International Gastric Cancer Congress, 2001.
 24. Balch GC, Mithani SK, Richards K, Beauchamp RD, **Kelley MC**. Prospective evaluation of the accuracy of lymphatic mapping and sentinel lymphadenectomy after preoperative therapy for locally advanced breast cancer. Presented at the Society of Surgical Oncology,

2002.

25. **Kelley MC**, Knobel SM, Carbone DP. Dendritic cells loaded with apoptotic melanoma cells slow tumor growth and improve survival in a murine immunotherapy model. Presented at the Society of Surgical Oncology, 2002.
26. Chakravarthy A, **Kelley MC**, Johnson D, Stewart Z, Beauchamp RD, Pearson AS, Merchant NB, Nicholson B, Stein R, Young R, Simpson J, Shyr Y, Pietenpol JA. Neoadjuvant paclitaxel/radiation for stage II/III breast cancer with correlative molecular markers. Proc Am Soc Clin Oncol 21:68a, 2002.
27. McCay J, **Kelley MC**, Schmidt CR, Simpson JF. Desmoplastic melanoma: Rare involvement of sentinel lymph nodes despite deep invasion. Presented at the US and Canadian Academy of Pathology, 2002.
28. Balch GC, Mithani SK, Shyr Y, Pearson AS, **Kelley MC**, Wise P, Chakravarthy A, Berlin J, Beauchamp RD, Merchant NB. Prognostic significance of response to neoadjuvant chemoradiation therapy for rectal cancer. Proc Am Soc Clin Oncol 22:261, 2003.
29. Chakravarthy A, Charaund P, **Kelley MC**, Johnson DH, Stewart Z, Truica C, Beauchamp RD, Pearson AS, Grau A, Simpson J, Shyr Y, Young R, Stein R, Pietenpol JA. Proteomic profiles from serial core biopsies following neoadjuvant paclitaxel/radiation for stage II/III breast cancer. Proc Am Soc Clin Oncol 22:860, 2003.
30. Wyman K, Atkins MB, Hubbard F, McDermott D, **Kelley MC**, Ko Y-J, Viar V, Mier J, Roberts S, Sosman JA. A phase II trial of imatinab mesylate at 800 mg in metastatic melanoma: lack of clinical efficacy with significant toxicity. Proc Am Soc Clin Oncol 22:713, 2003.
31. Kelley **MC**, Knobel SM, Carbone DP. Dendritic cells loaded with apoptotic allogeneic melanoma cells reduce tumor growth and improve survival in a murine immunotherapy model. Presented at the Association for Academic Surgery, 2003.
32. Lawson LL, Sandler M, Martin W, Beauchamp RD, **Kelley MC**. Preoperative lymphoscintigraphy and internal mammary sentinel lymph node biopsy does not enhance the accuracy of lymphatic mapping for breast cancer. Presented at the Southeastern Surgical Congress, 2004.
33. Balch GC, Mithani SK, Simpson J, **Kelley MC**. Accuracy of gross evaluation of surgical margin status in women undergoing partial mastectomy for breast cancer. Presented at the Southeastern Surgical Congress, 2004.
34. Schmidt CR, Yu C, Tarpley JL, Roberts JR, Pearson AS, **Kelley MC**, Ninan M, Berlin J, Chakravarthy A, Smalley WE, Beauchamp RD, Merchant NB. Complete response to neoadjuvant chemoradiation therapy for esophageal cancer does not improve survival. Presented at the Society for Surgical Oncology, 2004.
35. Chakravarthy A, Chaurand P, McLaren B, **Kelley MC**, Truica C, Erskine A, Simpson J, Billheimer D, Caprioli R, Pietenpol JA. Neoadjuvant paclitaxel/radiation for stage II/III breast cancer with correlative molecular markers. Presented at the American Society of

Clinical Oncology, 2004.

36. Chakravarthy A, McLaren B, **Kelley MC**, Mayer, I, Brown, C, Johnson KC, Simpson J, Billheimer D, Caprioli R, Pietenpol JA. Developing markers of therapeutic response using serial core biopsies during paclitaxel / radiation therapy in stage II/III breast cancer. Presented at the San Antonio Breast Cancer Symposium, 2004.
37. Forbes RC, Balch GC, **Kelley MC**. Selective Use of Intraoperative Touch Prep Analysis of Sentinel Nodes in Breast Cancer. Presented at the Southeastern Surgical Congress, 2005.
38. **Kelley MC**, Knobel S, Singh S, Sosman J. Cellular responses to PI3K/AKT and MAPK pathway inhibition in melanoma. Presented at the American Association of Cancer Research, 2005.
39. Yankeelov T, Lepage M, Niermann, KJ, Chakravarthy B, Herman CR, McManus K, **Kelley MC**, Meszoely I, Mayer I, Means J, Price RR, Pietenpol J, Gore JC. Quantitative Multi-Parametric MRI Assessment of Breast Cancer Treatment Response. Presented at the 5th Annual SPORE Symposium, 2005.
40. Hatmaker AH, Shipman J, Delbeke D, **Kelley MC**. The impact of FDG-PET staging on the management of patients with melanoma metastatic to the regional lymph nodes. Presented at the Society of Surgical Oncology, 2006.
41. Gray B, Knobel S, Nanney L, **Kelley MC**. Tissue Ischemia Does Not Alter Immunohistochemical Staining of MAPK and PI3K/AKT Pathway Phosphoproteins in a Human Melanoma Xenograft Model. Presented at the Society of Surgical Oncology, 2006.
42. Pitchford CW, **Kelley MC**, Simpson JF. Accuracy of Touch Prep Diagnosis of Breast Cancer Sentinel Lymph Nodes. Presented at the American Association of Pathology Meeting, 2006
43. Yankeelov T, LePage M, Chakravarthy AB, Niermann KJ, Herman CR, McManus K, **Kelley MC**, Mayer IA, Meszoely IM, Gore JC. Fast exchange regime analysis of the response to treatment in human breast cancer. Presented at the International Society for Magnetic Resonance in Medicine Meeting, 2006.
44. Hardesty WM, **Kelley MC**, Caprioli RM. Assessing protein signatures of metastatic melanoma by MALDI-MS. Presented at the American Society of Mass Spectrometry, 2006.
45. Chakravarthy AB, Yankeelov TE, Lepage M, **Kelley MC**, Meszoely IM, Mayer IA, Herman CR, McManus K, Price RR, Gore JC. Monitoring Treatment Response Following Neoadjuvant Chemotherapy Using Dynamic Contrast Enhanced Magnetic Resonance Imaging in Stage II/III Breast Cancer. Presented at the American Society for Therapeutic Radiology and Oncology (ASTRO), 2006
46. Chakravarthy AB., Mayer I.A., Meszoely I., **Kelley M.C.**, Means-Powell J., Johnson D.H., Granja N., Broome E.E., Pietenpol J.A. Phase II study of neoadjuvant dose-dense docetaxel in stage II/III breast cancer. Presented at the San Antonio Breast

Cancer Symposium, 2006.

47. Seeley E., Chakravarthy AB., Mi D., De Matos Granja N., Meszoely I., **Kelley M.C**, Mayer I., Means-Powell J., Johnson K., Caprioli R., and Pietenpol J.A. Histology-directed MALDI-TOF tissue profiling of breast tumors and adjacent stroma: developing markers of therapeutic response. Presented at the 29th Annual San Antonio Breast Cancer Symposium, 2006.
48. American Society of Breast Surgeons Quality and Patient Safety Committee: A Pilot Survey of the Quality of Breast Cancer Care Provided by Surgeons. Presented at the 9th Annual Meeting of The American Society of Breast Surgeons, April 30-May 4, 2008.
49. Chakravarthy AB, Mayer A, Meszoely I, **Kelley MC**, Means-Powell J, Frau AM, Johnson DH, Reddy R, Bauer JA, Pietenpol JA. Phase II study of neoadjuvant dose-dense docetaxel in stage II/III breast cancer. Presented at the American Society of Clinical Oncology, 2008.
50. Mansour AA, Schwartz H, Hatmaker A, Delbeke D, **Kelley MC** Musculoskeletal findings on FDG-PET-CT scans performed for melanoma staging. Presented at the Orthopaedic Research Society, 2008.
51. Hardesty W, **Kelley MC**, Deming M, Low R, Caprioli RM. Protein markers of survival in metastatic melanoma by histology-directed MALDI-MS. Presented at the American Society of Mass Spectrometry, 2008.
52. Keller MD, Majumder SK, **Kelley MC**, Meszoely IM, Boulos FI, Olivares GM, Mahadevan-Jansen A. Autofluorescence and diffuse reflectance spectroscopy and spectral imaging for surgical margin evaluation during breast cancer resection. Presented at the Society of Biomedical Optics, 2008.

INVITED LECTURES

1. University of Florida, Gainesville, FL. Surgery Grand Rounds. "Recent Advances in the Management of Melanoma". March 1996.
2. Arkansas Cancer Research Center, Little Rock, AK. Surgery Grand Rounds. "Recent Advances in the Management of Melanoma". February 1997.
3. Vanderbilt University Medical Center, Nashville, TN. Obstetrics and Gynecology Grand Rounds. "Evaluation and Management of Benign Breast Disease". October 1, 1997.
4. American Cancer Society Breast Cancer Forum, Nashville, TN. "Patient Choices: Surgical Treatment Options for Breast Cancer". October 18, 1997.
5. Vanderbilt University Medical Center, Nashville, TN. Surgery Grand Rounds. "Lymphatic Mapping and Sentinel Lymphadenectomy for Breast Cancer". November 1, 1997.
6. Bedford County Medical Center, Shelbyville, TN. "Recent Advances in the Management of Breast Cancer". November 6, 1997.
7. Vanderbilt University Medical Center, Nashville, TN. Medical Oncology Grand Rounds. "Surgical Management of Primary Breast Cancer" February 3, 1998.
8. Vanderbilt University Medical Center, Nashville, TN. Dermatology Grand Rounds. "Immunotherapy for Melanoma". February 12, 1998.
9. East Tennessee State University, Johnson City, TN. Surgery Grand Rounds. "Lymphatic Mapping and Sentinel Lymphadenectomy for Breast Cancer". March 14, 1998.
10. Tumor Registrar's Association of Tennessee Annual Meeting. Nashville, TN. "Current Management of Breast Cancer". March 20, 1998.
11. Clarksville Memorial Hospital, Clarksville, TN. "Recent Advances in the Surgical Management of Breast Cancer". July 17, 1998.
12. Maury Regional Hospital, Columbia, TN. "Recent Advances in the Management of Breast Cancer". October 15, 1998.
13. Vanderbilt University Medical Center, Nashville, TN. Department of Obstetrics and Gynecology Grand Rounds. "Recent Advances in the Management of Breast Cancer". February 17, 1999.
14. Vanderbilt University Medical Center, Nashville, TN. 1999 Lonnie S. Burnett Vanderbilt OB-GYN Society Meeting. "Tamoxifen and other SERMs for the Prevention of Breast Cancer". June 4, 1999.
15. The Genesys Hurley Cancer Institute, Hurley Medical Center, Flint, MI. Controversies in the Multi Modality Treatment of Breast Cancer. "Current Trends in the Surgical Management of Breast Cancer". October 13, 1999.
16. Cookeville Regional Cancer Center, Cookeville, TN. "Recent Advances in the Surgical Management of Breast Cancer". October 14, 1999.
17. Vanderbilt Department of Radiology, Nashville, TN. "Recent Advances in the Surgical Management of Breast Cancer". October 23, 1999.
18. Vanderbilt University School of Medicine, Nashville, TN. Women's Health Conference. Sponsored by Wyeth-Ayerst Labs, AstraZeneca Pharmaceuticals and UnitedHealthcare. "Recent Advances in the Detection, Treatment, and Prevention of Breast Cancer. November 20, 1999.
19. Vanderbilt University School of Medicine, Nashville, TN. High-Risk Obstetrics Seminar. Specialty Workshop: "Breast Cancer". December 3, 1999.
20. Bedford County Medical Center, Shelbyville, TN. "Breast Cancer Risk Evaluation and Management". January 6, 2000.
21. Vanderbilt-Ingram Cancer Center Affiliate Network, Nashville TN. "Clinical Trials for Women at High Risk of Developing Breast Cancer". March 4, 2000.
22. Cumberland Regional Medical Center, Crossville, TN. "Recent Advances in the

- Management of Breast Cancer". May 2, 2000.
23. Bedford County Medical Center, Shelbyville, TN. "Recent Advances in the Management of Melanoma". June 22, 2000.
 24. Heartland Medical Center, Elizabethtown KY. "Recent Advances in the Management of Melanoma". August 19, 2000.
 25. Harton Regional Medical Center, Tullahoma, TN. "Breast Cancer Risk Evaluation and Management". September 14, 2000.
 26. Maury Regional Hospital, Columbia, TN. "Breast Cancer Risk Evaluation and Management". October 12, 2000.
 27. Susan B. Komen Foundation Breast Cancer Symposium, Nashville, TN. "Breast Cancer Diagnosis and Surgical Treatment". March 31, 2001.
 28. Vanderbilt University Medical Center Division of Ambulatory Medicine, Nashville, TN. "Evaluation of Common Breast Complaints". October 5, 2001.
 29. Vanderbilt University Medical Center, Nashville, TN. Department of Obstetrics and Gynecology Grand Rounds. "Update on the Management of Melanoma". December 5, 2001.
 30. Vanderbilt University Medical Center, Nashville, TN. Department of Surgery Grand Rounds. "Prophylactic Mastectomy: Indications, Risks, Benefits" January 18th, 2002.
 31. Vanderbilt University Medical Center, Nashville TN. Cancer Genetics Symposium "Breast Cancer Risk Reduction Strategies" January 19th, 2002.
 32. The University of Florida, Gainesville FL. Edward M. Copeland III Scientific Symposium. "New Approaches to Immunotherapy of Melanoma" March 1st, 2002.
 33. Vanderbilt University Medical Center, Nashville, TN. Department of Surgery Grand Rounds. "Immunotherapy of melanoma: From Bench to Bedside and Back Again" September 13th, 2002.
 34. Vanderbilt University Medical Center, Nashville, TN. Department of Cancer Biology. "Tumor Immunology and Immunotherapy" November 11th, 2002.
 35. Society of Surgical Oncology, Los Angeles CA. Moderator, Breast Cancer Parallel Session, March 7th, 2003.
 36. Vanderbilt University Medical Center, Nashville, TN. Melanoma Research Conference. "Preclinical Studies of Molecular Targeted Therapy of Melanoma: A Work in Progress" March 19th, 2003.
 37. Cumberland Regional Medical Center, Crossville, TN. "Controversies in the Treatment of Melanoma". June 3, 2003.
 38. Maury Regional Hospital, Columbia, TN. "Current Management of Melanoma". September 10, 2003.
 39. Vanderbilt University Medical Center, Nashville, TN. Department of Surgery Grand Rounds. "Evaluation and Management of Common Breast Conditions" October 3, 2003.
 40. Belleview Mall, Nashville, TN. "Cancer Answer Evening: Breast Cancer – Ask the Expert" October 7, 2003.
 41. Vanderbilt University Medical Center, Nashville, TN. Department of Surgery Grand Rounds. "Breast Cancer Treatment" October 10, 2003.
 42. Vanderbilt University Medical Center, Nashville, TN. "Cancer Answer Evening: Breast Cancer – The Crusade Marches On" October 7, 2003.
 43. Vanderbilt University Medical Center, Nashville, TN. Department of Surgery Grand Rounds. "Melanoma Management" October 24, 2003.
 44. Vanderbilt University Medical Center, Nashville, TN. Department of Cancer Biology. "Tumor Immunology and Immunotherapy" November 3, 2003.
 45. Erlanger Medical Center, Chattanooga TN. Department of Surgery Grand Rounds. "Melanoma Management" November 5, 2003.

46. Williamson County Medical Center, Franklin TN. "Recent Advances in the Surgical Treatment of Breast Cancer" November 6, 2003.
47. Vanderbilt University Medical Center, Nashville, TN. Department of Surgery Resident Teaching Conference. "Tumor Immunology and Immunotherapy" December 12, 2003.
48. Vanderbilt University Medical Center, Nashville, TN. Oncology Conference. "Breast Cancer Risk Evaluation and Management". January 23, 2004.
49. Vanderbilt University Medical Center, Nashville, TN. School of Nursing Grand Rounds. "Management of Common Breast Conditions" April, 2004.
50. Vanderbilt University Medical Center, Nashville, TN. Oncology Conference. "Surgical treatment of melanoma". April 26, 2005.
51. Vanderbilt University Medical Center, Nashville, TN. Multidisciplinary Melanoma Symposium. "Sentinel lymph node biopsy for melanoma". September 16, 2005.
52. Vanderbilt University Medical Center, Nashville, TN. Cancer Biology Research Seminar. "Cellular responses to MAP kinase and PI-3 kinase / AKT pathway inhibition in melanoma. February 13, 2006.
53. Vanderbilt University Medical Center, Nashville, TN. Surgical Oncology Research Seminar. "Pre-clinical models of molecular therapy targeting the MAP kinase and PI-3 kinase / AKT pathways in melanoma". February 20, 2006.
54. Vanderbilt University Medical School, Nashville, TN. Introduction to Clinical Medicine Lecture. "Clinical evaluation of breast diseases". April 18, 2006.
55. Vanderbilt University Medical School, Nashville, TN. Primary Care Update. "Evaluation of palpable abnormalities of the breast". May 18, 2006.
56. Vanderbilt University Medical Center, Nashville, TN. Plastic Surgery Teaching Conference. "Melanoma Update: 2006". June 22, 2006.
57. University of Tennessee, Knoxville TN. Department of Surgery Grand Rounds. "Treatment of High-Risk Melanoma: Progress or futility?" March 29, 2007.
58. Community Methodist Hospital, Hendersonville, KY. Oncology Conference. "Breast cancer risk evaluation and management" August 29, 2007.
59. Vanderbilt University Medical Center, Nashville, TN. Department of Surgery Grand Rounds. "Melanoma 2007: Have we made any progress?" September 7th, 2007.
60. Tennessee Academy of Physician's Assistants Annual Meeting, Gatlinburg, TN. "Breast cancer screening and treatment, 2007" October 9, 2007.
61. Vanderbilt University Medical Center MCE Grand Rounds. "Surgical treatment of breast cancer: Practical information for OR staff and anesthesia providers" January 9, 2008
62. University Medical Center, Lebanon, TN. "Breast cancer risk evaluation and management" February 12th, 2008.
63. Vanderbilt University Medical Center, Nashville, TN. Department of Dermatology Grand Rounds. "Surgical treatment of high-risk melanoma" April 9th, 2009.
64. Northcrest Medical Center, Springfield TN. "Surgical treatment of high-risk melanoma" June 18th, 2009.
65. Heritage Medical Group, Nashville TN. "Breast cancer risk evaluation and management" September 18th, 2009.